Gastric Cancer Clinical Trials in San Francisco, California

4 studies are recruiting for gastric cancer in San Francisco, California right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors

    This is an open-label, multi-center, phase I study to evaluate the safety, tolerability, efficacy, and pharmacokinetics of MRG007 (ARR-217) in patients with unresectable locally advanced or metastatic solid tumors.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    UCSF, San Francisco, California
    Locations
    21 in total
    Run by
    ArriVent BioPharma, Inc.

    See if you can join NCT07066657 on ClinicalTrials.gov

  2. A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

    The goal of the Dose Escalation phase of the study is to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity to determine the preliminary recommended dose for expansion (RDE) of NKT3964 in adults with advanced or metastatic solid tumors. The goal of the Expa…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    UCSF, San Francisco, California
    Locations
    19 in total
    Run by
    NiKang Therapeutics, Inc.

    See if you can join NCT06586957 on ClinicalTrials.gov

  3. A Study of NX-1607 in Adults With Advanced Malignancies

    This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients with advanced malignancies.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    University of California, San Francisco, San Francisco, California
    Locations
    17 in total
    Run by
    Nurix Therapeutics, Inc.

    See if you can join NCT05107674 on ClinicalTrials.gov

  4. A Beta-only IL-2 ImmunoTherapY Study

    This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a checkpoint inhibitor in patients with advanced solid tumors.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California
    Locations
    27 in total
    Run by
    Medicenna Therapeutics, Inc.

    See if you can join NCT05086692 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.